Investigational drug · Phase 2
BBT001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Spontaneous Urticaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BBT001"
First trial start
2026
Jun 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBT001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Spontaneous Urticaria
Approved drugs for the same conditions: Chronic hives (urticaria) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "BBT001" as an intervention, largest first.
- A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)Pivotal-lookingRecruiting
Bambusa TherapeuticsIndustry
NCT06808477 · 237 participants (planned) · Start Feb 27, 2025 · Primary completion Feb 28, 2027
Drug: BBT001; Placebo · For: Atopic Dermatitis
Sites: Irvine, California; New York, New York; The Bronx, New York · 14 sites in all
Bambusa TherapeuticsIndustry
NCT07239947 · 99 participants (planned) · Start Aug 9, 2025 · Primary completion Dec 31, 2027
Drug: BBT001; Placebo · For: Atopic Dermatitis
Sites: Hefei, China; Wuhu, China; Beijing, China · 10 sites in all
Bambusa TherapeuticsIndustry
NCT07717905 · 48 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 31, 2027
Drug: BBT001; Placebo · For: Chronic Spontaneous Urticaria
Sites: Wuhu, China; Beijing, China; Guangzhou, China · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Spontaneous Urticaria
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- JYB1904RPT904, ozureprubartPhase 35 trials
Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BLU-808Phase 22 trials
Blueprint Medicines Corporation · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.